Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.Partnership >
Medivir presents MIV-818 data at AACR-NCI-EORTC in BostonRead more
US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapyRead more
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019Read more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.